| Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual‐acting angiotensin receptor—neprilysin inhibitor (ARNi) J Gu, A Noe, P Chandra, S Al‐Fayoumi, M Ligueros‐Saylan, ... The Journal of Clinical Pharmacology 50 (4), 401-414, 2010 | 654 | 2010 |
| Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial J Mascarenhas, R Hoffman, M Talpaz, AT Gerds, B Stein, V Gupta, ... JAMA oncology 4 (5), 652-659, 2018 | 374 | 2018 |
| Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy JW Singer, A Fleischman, S Al-Fayoumi, JO Mascarenhas, Q Yu, ... Oncotarget 9 (70), 33416, 2018 | 137 | 2018 |
| Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor JW Singer, S Al-Fayoumi, H Ma, RS Komrokji, R Mesa, S Verstovsek Journal of Experimental Pharmacology, 11-19, 2016 | 117 | 2016 |
| Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies S Verstovsek, O Odenike, JW Singer, T Granston, S Al-Fayoumi, HJ Deeg Journal of Hematology & Oncology 9, 1-12, 2016 | 86 | 2016 |
| Phase 1, dose-ranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers RYO Kubota, S Al-Fayoumi, S Mallikaarjun, S Patil, C Bavik, JW Chandler Retina 34 (3), 603-609, 2014 | 86 | 2014 |
| Results of the Persist-2 phase 3 study of pacritinib (PAC) versus best available therapy (BAT), including ruxolitinib (RUX), in patients (pts) with myelofibrosis (MF) and … J Mascarenhas, R Hoffman, M Talpaz, AT Gerds, B Stein, V Gupta, ... Blood 128 (22), LBA-5, 2016 | 56 | 2016 |
| Pharmacokinetics and pharmacodynamics of dexamethasone sodium‐m‐sulfobenzoate (DS) after intravenous and intramuscular administration: a comparison with dexamethasone phosphate … G Hochhaus, J Barth, S Al‐Fayoumi, S Suarez, H Derendorf, R Hochhaus, ... The Journal of Clinical Pharmacology 41 (4), 425-434, 2001 | 54 | 2001 |
| Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures JW Singer, S Al-Fayoumi, J Taylor, S Velichko, A O’Mahony PLoS One 14 (9), e0222944, 2019 | 46 | 2019 |
| Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis S Al-Fayoumi, T Hashiguchi, Y Shirakata, J Mascarenhas, JW Singer Journal of Experimental Pharmacology, 9-17, 2018 | 26 | 2018 |
| Tolerability and toxicological profile of pixantrone (Pixuvri®) in juvenile mice. Comparative study with doxorubicin M Longo, P Della Torre, C Allievi, A Morisetti, S Al-Fayoumi, JW Singer Reproductive Toxicology 46, 20-30, 2014 | 24 | 2014 |
| Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX) J Mascarenhas, R Hoffman, M Talpaz, AT Gerds, B Stein, V Gupta, ... Patients (pts) with Myelofibrosis (MF) and Platelet Counts 100, 3-6, 0 | 14 | |
| Comprehensive kinase profile of pacritinib, a non-myelosuppressive JAK2 kinase inhibitor in phase 3 development in primary and post ET/PV myelofibrosis J Singer, S Al-Fayoumi, H Ma, RS Komrokji, R Mesa, S Verstovsek Blood, The Journal of the American Society of Hematology 124 (21), 1874-1874, 2014 | 13 | 2014 |
| Exposure-response analysis for pacritinib (SB1518), a novel oral JAK2/FLT3 inhibitor, in patients with myelofibrosis S Al-Fayoumi, L Wang, H Li, R Wada, JP Dean Blood 122 (21), 4080, 2013 | 10 | 2013 |
| Dual acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and ne utral endopeptidase (ep) inhibitor S Al-Fayoumi, J Hu, N Kumaraperumal, AE Royce, C Ruegger, ... US Patent App. 12/741,251, 2010 | 10 | 2010 |
| Identification of stabilized dynorphin derivatives for suppressing tolerance in morphine-dependent rats SI Al-Fayoumi, B Brugos, V Arya, E Mulder, B Eppler, AP Mauderli, ... Pharmaceutical research 21, 1450-1456, 2004 | 9 | 2004 |
| Pharmacokinetics, safety and tolerability of single and multiple oral doses of aliskiren in healthy Chinese subjects: a randomized, single-blind, parallel-group, placebo … P Hu, M Bartlett, RS Karan, J Jiang, S Zhang, J Zhang, D Howard, ... Clinical drug investigation 30, 221-228, 2010 | 8 | 2010 |
| Comparative biomarker profiles of pacritinib, momelotinib, pexidartinib, and ruxolitinib using BioMAP Diversity PLUS panel S Al-Fayoumi, R Watson, A O'Mahony, JW Singer European Journal of Cancer 1 (69), S136, 2016 | 4 | 2016 |
| Multiple-dose pharmacokinetics of the direct renin inhibitor aliskiren in healthy Chinese subjects. M Bartlett, S Vaidyanathan, RS Karan, P Hu, D Howard, CM Yeh, ... CLINICAL PHARMACOLOGY & THERAPEUTICS 83, S61-S62, 2008 | 3 | 2008 |
| Characterization of the pharmacokinetic and pharmacodynamic properties of pacritinib, a novel oral JAK2/FLT3 inhibitor, in patients with myelofibrosis, AML, and lymphoma S Al-Fayoumi, L Wang, JP Dean, S Benner 18th Congress of the European Hematology Association, 2013 | 2 | 2013 |
